|
Immunotherapy (Pembrolizumab) Clinical Trials
4 actively recruiting trials across 2 locations
Also known as: Pembrolizumab
Pipeline
Phase 2: 2Phase 2/3: 2
Top Sponsors
- The University of Texas Health Science Center, Houston1
- Peking Union Medical College Hospital1
- Linnaeus Therapeutics, Inc.1
- CNAO National Center of Oncological Hadrontherapy1
Indications
- Cancer4
- Melanoma Stage IIIB-IV1
- Melanoma (Skin Cancer)1
- Locally Advanced Esophageal Squamous Cell Carcinoma1
- Unresectable Melanoma1
Other2 trials
Newport Beach, California1 trial
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
USC Newport Beach
Phase 2/3
Houston, Texas1 trial
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
The University of Texas Health Science Center at Houston
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.